The activation of CXCR7 by its physiological ligands results in the activation of Akt [30] and ERK kinase [31], and enhances survival and proliferation of myeloma cells in vitro[32], [33], similar pattern of events that we observed after the AMD3100 treatment. Here, ACKR3 is linked to plasma cell myeloma.